NOVAVAX INC (NVAX) Form 10-Q — Nov 5, 2026
Novavax reported Q3 2026 revenue of $68.3 million and a net loss of $31.4 million ($0.19 per share), a dramatic improvement from the year-ago quarter's $202.4 million net loss, driven by deep cost cuts including a $45.8 million reduction in R&D spending. Nine-month revenue fell to $264.5 million from $976.3 million, primarily because 2025 included one-time revenue from terminated Canada and New Zealand advance purchase agreements, while the company has transitioned commercial leadership of Nuvaxovid to Sanofi.
Key figures
- Revenue
- 68298000
- Total Debt
- 292088000
- Revenue Yoy
- -$2.1M Q3 YoY; nine-month revenue $264.5M vs $976.3M (-$711.8M)
- Total Assets
- 888005000
- Cash Position
- 627000000
- Shares Outstanding
- 165009009
- Working capital
- 378100000
- Midcap funded at closing
- 50000000
- Midcap credit facility total
- 330000000
- Australia apa potential refund
- up to $92.5 million of deferred revenue may become refundable
- Credit agreement interest rate
- 8.7% (Term SOFR + 5.00%)
- Sanofi q3 cic milestone earned
- 125000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.